GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Realcan Pharmaceutical Group Co Ltd (SZSE:002589) » Definitions » Research & Development

Realcan Pharmaceutical Group Co (SZSE:002589) Research & Development : ¥22 Mil (TTM As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Realcan Pharmaceutical Group Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Realcan Pharmaceutical Group Co's Research & Development for the three months ended in Sep. 2023 was ¥4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was ¥22 Mil.


Realcan Pharmaceutical Group Co Research & Development Historical Data

The historical data trend for Realcan Pharmaceutical Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Realcan Pharmaceutical Group Co Research & Development Chart

Realcan Pharmaceutical Group Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6.97 8.91 11.56 22.68

Realcan Pharmaceutical Group Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 12.32 2.85 3.42 3.91

Realcan Pharmaceutical Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Realcan Pharmaceutical Group Co  (SZSE:002589) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Realcan Pharmaceutical Group Co Research & Development Related Terms

Thank you for viewing the detailed overview of Realcan Pharmaceutical Group Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Realcan Pharmaceutical Group Co (SZSE:002589) Business Description

Traded in Other Exchanges
N/A
Address
No. 326, Airport Road, Zhifu District, Shandong Province, Yantai, CHN, 264004
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.

Realcan Pharmaceutical Group Co (SZSE:002589) Headlines

No Headlines